1
|
Broxmeyer HE, Luchsinger LL, Weinberg RS, Jimenez A, Frenet EM, Van't Hof W, Capitano ML, Hillyer CD, Kaplan MH, Cooper S, Ropa J. Insights into highly engraftable hematopoietic cells from 27-year cryopreserved umbilical cord blood. Cell Rep Med 2023; 4:101259. [PMID: 37913777 PMCID: PMC10694620 DOI: 10.1016/j.xcrm.2023.101259] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2023] [Revised: 09/02/2023] [Accepted: 10/04/2023] [Indexed: 11/03/2023]
Abstract
Umbilical cord blood transplantation is a life-saving treatment for malignant and non-malignant hematologic disorders. It remains unclear how long cryopreserved units remain functional, and the length of cryopreservation is often used as a criterion to exclude older units. We demonstrate that long-term cryopreserved cord blood retains similar numbers of hematopoietic stem and progenitor cells compared with fresh and recently cryopreserved cord blood units. Long-term cryopreserved units contain highly functional cells, yielding robust engraftment in mouse transplantation models. We also leverage differences between units to examine gene programs associated with better engraftment. Transcriptomic analyses reveal that gene programs associated with lineage determination and oxidative stress are enriched in high engrafting cord blood, revealing potential molecular markers to be used as potency markers for cord blood unit selection regardless of length of cryopreservation. In summary, cord blood units cryopreserved for extended periods retain engrafting potential and can potentially be used for patient treatment.
Collapse
Affiliation(s)
- Hal E Broxmeyer
- Department of Microbiology & Immunology, Indiana University School of Medicine, Indianapolis, IN 46202, USA
| | | | | | - Alexandra Jimenez
- Comprehensive Cell Solutions, New York Blood Center, New York, NY 10065, USA; National Cord Blood Program, Long Island City, NY 11101, USA
| | - Emeline Masson Frenet
- Comprehensive Cell Solutions, New York Blood Center, New York, NY 10065, USA; National Cord Blood Program, Long Island City, NY 11101, USA
| | | | - Maegan L Capitano
- Department of Microbiology & Immunology, Indiana University School of Medicine, Indianapolis, IN 46202, USA
| | | | - Mark H Kaplan
- Department of Microbiology & Immunology, Indiana University School of Medicine, Indianapolis, IN 46202, USA
| | - Scott Cooper
- Department of Microbiology & Immunology, Indiana University School of Medicine, Indianapolis, IN 46202, USA.
| | - James Ropa
- Department of Microbiology & Immunology, Indiana University School of Medicine, Indianapolis, IN 46202, USA.
| |
Collapse
|
2
|
Shi PA, Luchsinger LL, Greally JM, Delaney CS. Umbilical cord blood: an undervalued and underutilized resource in allogeneic hematopoietic stem cell transplant and novel cell therapy applications. Curr Opin Hematol 2022; 29:317-326. [PMID: 36066376 PMCID: PMC9547826 DOI: 10.1097/moh.0000000000000732] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
PURPOSE OF REVIEW The purpose of this review is to primarily discuss the unwarranted decline in the use of umbilical cord blood (UCB) as a source of donor hematopoietic stem cells (HSC) for hematopoietic cell transplantation (HCT) and the resulting important implications in addressing healthcare inequities, and secondly to highlight the incredible potential of UCB and related birthing tissues for the development of a broad range of therapies to treat human disease including but not limited to oncology, neurologic, cardiac, orthopedic and immunologic conditions. RECENT FINDINGS When current best practices are followed, unrelated donor umbilical cord blood transplant (CBT) can provide superior quality of life-related survival compared to other allogeneic HSC donor sources (sibling, matched or mismatched unrelated, and haploidentical) through decreased risks of relapse and chronic graft vs. host disease. Current best practices include improved UCB donor selection criteria with consideration of higher resolution human leukocyte antigen (HLA) typing and CD34+ cell dose, availability of newer myeloablative but reduced toxicity conditioning regimens, and rigorous supportive care in the early posttransplant period with monitoring for known complications, especially related to viral and other infections that may require intervention. Emerging best practice may include the use of ex vivo expanded single-unit CBT rather than double-unit CBT (dCBT) or 'haplo-cord' transplant, and the incorporation of posttransplant cyclophosphamide as with haploidentical transplant and/or incorporation of novel posttransplant therapies to reduce the risk of relapse, such as NK cell adoptive transfer. Novel, non-HCT uses of UCB and birthing tissue include the production of UCB-derived immune effector cell therapies such as unmodified NK cells, chimeric antigen receptor-natural killer cells and immune T-cell populations, the isolation of mesenchymal stem cells for immune modulatory treatments and derivation of induced pluripotent stem cells haplobanks for regenerative medicine development and population studies to facilitate exploration of drug development through functional genomics. SUMMARY The potential of allogeneic UCB for HCT and novel cell-based therapies is undervalued and underutilized. The inventory of high-quality UCB units available from public cord blood banks (CBB) should be expanding rather than contracting in order to address ongoing healthcare inequities and to maintain a valuable source of cellular starting material for cell and gene therapies and regenerative medicine approaches. The expertise in Good Manufacturing Practice-grade manufacturing provided by CBB should be supported to effectively partner with groups developing UCB for novel cell-based therapies.
Collapse
Affiliation(s)
- Patricia A. Shi
- Lindsley F. Kimball Research Institute, New York Blood Center, New York City, NY 10065
| | - Larry L. Luchsinger
- Lindsley F. Kimball Research Institute, New York Blood Center, New York City, NY 10065
| | - John M. Greally
- Department of Genetics, Albert Einstein College of Medicine, Bronx, NY 10461
| | - Colleen S. Delaney
- Division of Hematology-Oncology, Seattle Children’s Hospital, Seattle WA; and Department of Pediatrics, University of Washington School of Medicine, Seattle, WA 98195
- Deverra Therapeutics, Inc., Seattle, WA 98102
| |
Collapse
|
3
|
Haynes WA, Kamath K, Bozekowski J, Baum-Jones E, Campbell M, Casanovas-Massana A, Daugherty PS, Dela Cruz CS, Dhal A, Farhadian SF, Fitzgibbons L, Fournier J, Jhatro M, Jordan G, Klein J, Lucas C, Kessler D, Luchsinger LL, Martinez B, Catherine Muenker M, Pischel L, Reifert J, Sawyer JR, Waitz R, Wunder EA, Zhang M, Iwasaki A, Ko A, Shon JC. High-resolution epitope mapping and characterization of SARS-CoV-2 antibodies in large cohorts of subjects with COVID-19. Commun Biol 2021; 4:1317. [PMID: 34811480 PMCID: PMC8608966 DOI: 10.1038/s42003-021-02835-2] [Citation(s) in RCA: 21] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/25/2021] [Accepted: 10/22/2021] [Indexed: 12/12/2022] Open
Abstract
As Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) continues to spread, characterization of its antibody epitopes, emerging strains, related coronaviruses, and even the human proteome in naturally infected patients can guide the development of effective vaccines and therapies. Since traditional epitope identification tools are dependent upon pre-defined peptide sequences, they are not readily adaptable to diverse viral proteomes. The Serum Epitope Repertoire Analysis (SERA) platform leverages a high diversity random bacterial display library to identify proteome-independent epitope binding specificities which are then analyzed in the context of organisms of interest. When evaluating immune response in the context of SARS-CoV-2, we identify dominant epitope regions and motifs which demonstrate potential to classify mild from severe disease and relate to neutralization activity. We highlight SARS-CoV-2 epitopes that are cross-reactive with other coronaviruses and demonstrate decreased epitope signal for mutant SARS-CoV-2 strains. Collectively, the evolution of SARS-CoV-2 mutants towards reduced antibody response highlight the importance of data-driven development of the vaccines and therapies to treat COVID-19. Using a high throughput, random bacterial peptide display approach applied to patient serum samples, Haynes, Kamath, Bozekowski et al identify the antigens and epitopes that elicit a SARS-CoV-2 humoral response. They identify differences depending on disease severity and further in silico analysis suggests decreased epitope signal for Q677P but not for D614G mutant SARSCoV-2 strains.
Collapse
Affiliation(s)
| | | | | | | | - Melissa Campbell
- Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA
| | - Arnau Casanovas-Massana
- Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA
| | | | - Charles S Dela Cruz
- Department of Medicine, Section of Pulmonary and Critical Care Medicine, Yale University School of Medicine, New Haven, CT, USA
| | | | - Shelli F Farhadian
- Department of Medicine, Section of Infectious Diseases, Yale University School of Medicine, New Haven, CT, USA
| | | | - John Fournier
- Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA
| | | | | | - Jon Klein
- Department of Immunobiology, Yale University School of Medicine, New Haven, CT, USA
| | - Carolina Lucas
- Department of Immunobiology, Yale University School of Medicine, New Haven, CT, USA
| | | | | | | | - M Catherine Muenker
- Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA
| | - Lauren Pischel
- Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA.,Department of Medicine, Section of Infectious Diseases, Yale University School of Medicine, New Haven, CT, USA
| | | | | | | | - Elsio A Wunder
- Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA
| | | | | | - Akiko Iwasaki
- Department of Immunobiology, Yale University School of Medicine, New Haven, CT, USA.,Howard Hughes Medical Institute, Chevy Chase, MD, USA
| | - Albert Ko
- Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA
| | | |
Collapse
|
4
|
Abstract
PURPOSE OF REVIEW Hematopoietic stem cells (HSCs) possess the ability to regenerate over a lifetime in the face of extreme cellular proliferation and environmental stress. Yet, mechanisms that control the regenerative properties of HSCs remain elusive. ER stress has emerged as an important signaling event that supports HSC self-renewal and multipotency. The purpose of this review is to summarize the pathways implicating ER stress as cytoprotective in HSCs. RECENT FINDINGS Recent studies have shown multiple signaling cascades of the unfolded protein response (UPR) are persistently activated in healthy HSCs, suggesting that low-dose ER stress is a feature HSCs. Stress adaptation is a feature ascribed to cytoprotection and longevity of cells as well as organisms, in what is known as hormesis. However, assembling this information into useful knowledge to improve the therapeutic application of HSCs remains challenging and the upstream activators and downstream transcriptional programs induced by ER stress that are required in HSCs remain to be discovered. SUMMARY The maintenance of HSCs requires a dose-dependent simulation of ER stress responses that involves persistent, low-dose UPR. Unraveling the complexity of this signaling node may elucidate mechanisms related to regeneration of HSCs that can be harnessed to expand HSCs for cellular therapeutics ex vivo and transplantation in vivo.
Collapse
Affiliation(s)
- Larry L Luchsinger
- Lindsley F. Kimball Research Institute, New York Blood Center, New York City, New York, USA
| |
Collapse
|
5
|
Nesbitt DJ, Jin DP, Hogan JW, Yang J, Chen H, Chan PA, Simon MJ, Vargas M, King E, Huard RC, Bandy U, Hillyer CD, Luchsinger LL. Low Seroprevalence of SARS-CoV-2 in Rhode Island blood donors during may 2020 as determined using multiple serological assay formats. BMC Infect Dis 2021. [PMID: 34433423 DOI: 10.1101/2020.07.20.20157743] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/28/2023] Open
Abstract
BACKGROUND Epidemic projections and public health policies addressing Coronavirus disease (COVID)-19 have been implemented without data reporting on the seroconversion of the population since scalable antibody testing has only recently become available. METHODS We measured the percentage of severe acute respiratory syndrome- Coronavirus-2 (SARS-CoV-2) seropositive individuals from 2008 blood donors drawn in the state of Rhode Island (RI). We utilized multiple antibody testing platforms, including lateral flow immunoassays (LFAs), enzyme-linked immunosorbent assays (ELISAs) and high throughput serological assays (HTSAs). To estimate seroprevalence, we utilized the Bayesian statistical method to adjust for sensitivity and specificity of the commercial tests used. RESULTS We report than an estimated seropositive rate of RI blood donors of approximately 0.6% existed in April-May of 2020. Daily new case rates peaked in RI in late April 2020. We found HTSAs and LFAs were positively correlated with ELISA assays to detect antibodies specific to SARS-CoV-2 in blood donors. CONCLUSIONS These data imply that seroconversion, and thus infection, is likely not widespread within this population. We conclude that IgG LFAs and HTSAs are suitable to conduct seroprevalence assays in random populations. More studies will be needed using validated serological tests to improve the precision and report the kinetic progression of seroprevalence estimates.
Collapse
Affiliation(s)
- Daniel J Nesbitt
- New York Blood Center, Lindsley F. Kimball Research Institute, New York, NY, USA
| | - Daniel P Jin
- New York Blood Center, Lindsley F. Kimball Research Institute, New York, NY, USA
| | - Joseph W Hogan
- Department of Biostatistics, Brown University, Providence, RI, USA
| | - Jenny Yang
- New York Blood Center, Lindsley F. Kimball Research Institute, New York, NY, USA
| | - Haidee Chen
- New York Blood Center, Lindsley F. Kimball Research Institute, New York, NY, USA
| | - Philip A Chan
- Rhode Island Department of Health, Providence, RI, USA
| | | | | | - Ewa King
- Rhode Island Department of Health, Providence, RI, USA
- Rhode Island State Health Laboratory, Providence, RI, USA
| | - Richard C Huard
- Rhode Island Department of Health, Providence, RI, USA
- Rhode Island State Health Laboratory, Providence, RI, USA
| | - Utpala Bandy
- Rhode Island Department of Health, Providence, RI, USA
| | | | - Larry L Luchsinger
- New York Blood Center, Lindsley F. Kimball Research Institute, New York, NY, USA.
| |
Collapse
|
6
|
Nesbitt DJ, Jin DP, Hogan JW, Yang J, Chen H, Chan PA, Simon MJ, Vargas M, King E, Huard RC, Bandy U, Hillyer CD, Luchsinger LL. Low Seroprevalence of SARS-CoV-2 in Rhode Island blood donors during may 2020 as determined using multiple serological assay formats. BMC Infect Dis 2021; 21:871. [PMID: 34433423 PMCID: PMC8386143 DOI: 10.1186/s12879-021-06438-4] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2020] [Accepted: 07/14/2021] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND Epidemic projections and public health policies addressing Coronavirus disease (COVID)-19 have been implemented without data reporting on the seroconversion of the population since scalable antibody testing has only recently become available. METHODS We measured the percentage of severe acute respiratory syndrome- Coronavirus-2 (SARS-CoV-2) seropositive individuals from 2008 blood donors drawn in the state of Rhode Island (RI). We utilized multiple antibody testing platforms, including lateral flow immunoassays (LFAs), enzyme-linked immunosorbent assays (ELISAs) and high throughput serological assays (HTSAs). To estimate seroprevalence, we utilized the Bayesian statistical method to adjust for sensitivity and specificity of the commercial tests used. RESULTS We report than an estimated seropositive rate of RI blood donors of approximately 0.6% existed in April-May of 2020. Daily new case rates peaked in RI in late April 2020. We found HTSAs and LFAs were positively correlated with ELISA assays to detect antibodies specific to SARS-CoV-2 in blood donors. CONCLUSIONS These data imply that seroconversion, and thus infection, is likely not widespread within this population. We conclude that IgG LFAs and HTSAs are suitable to conduct seroprevalence assays in random populations. More studies will be needed using validated serological tests to improve the precision and report the kinetic progression of seroprevalence estimates.
Collapse
Affiliation(s)
- Daniel J Nesbitt
- New York Blood Center, Lindsley F. Kimball Research Institute, New York, NY, USA
| | - Daniel P Jin
- New York Blood Center, Lindsley F. Kimball Research Institute, New York, NY, USA
| | - Joseph W Hogan
- Department of Biostatistics, Brown University, Providence, RI, USA
| | - Jenny Yang
- New York Blood Center, Lindsley F. Kimball Research Institute, New York, NY, USA
| | - Haidee Chen
- New York Blood Center, Lindsley F. Kimball Research Institute, New York, NY, USA
| | - Philip A Chan
- Rhode Island Department of Health, Providence, RI, USA
| | | | | | - Ewa King
- Rhode Island Department of Health, Providence, RI, USA
- Rhode Island State Health Laboratory, Providence, RI, USA
| | - Richard C Huard
- Rhode Island Department of Health, Providence, RI, USA
- Rhode Island State Health Laboratory, Providence, RI, USA
| | - Utpala Bandy
- Rhode Island Department of Health, Providence, RI, USA
| | | | - Larry L Luchsinger
- New York Blood Center, Lindsley F. Kimball Research Institute, New York, NY, USA.
| |
Collapse
|
7
|
Jin DK, Nesbitt DJ, Yang J, Chen H, Horowitz J, Jones M, Vandergaast R, Carey T, Reiter S, Russell SJ, Kyratsous C, Hooper A, Hamilton J, Ferreira M, Deng S, Straus D, Baras A, Hillyer CD, Luchsinger LL. Seroprevalence of anti-SARS-CoV-2 antibodies in a cohort of New York City metro blood donors using multiple SARS-CoV-2 serological assays: Implications for controlling the epidemic and "Reopening". PLoS One 2021; 16:e0250319. [PMID: 33909646 PMCID: PMC8081167 DOI: 10.1371/journal.pone.0250319] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2020] [Accepted: 04/05/2021] [Indexed: 02/06/2023] Open
Abstract
Projections of the stage of the Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) pandemic and local, regional and national public health policies to limit coronavirus spread as well as "reopen" cities and states, are best informed by serum neutralizing antibody titers measured by reproducible, high throughput, and statically credible antibody (Ab) assays. To date, a myriad of Ab tests, both available and FDA authorized for emergency, has led to confusion rather than insight per se. The present study reports the results of a rapid, point-in-time 1,000-person cohort study using serial blood donors in the New York City metropolitan area (NYC) using multiple serological tests, including enzyme-linked immunosorbent assays (ELISAs) and high throughput serological assays (HTSAs). These were then tested and associated with assays for neutralizing Ab (NAb). Of the 1,000 NYC blood donor samples in late June and early July 2020, 12.1% and 10.9% were seropositive using the Ortho Total Ig and the Abbott IgG HTSA assays, respectively. These serological assays correlated with neutralization activity specific to SARS-CoV-2. The data reported herein suggest that seroconversion in this population occurred in approximately 1 in 8 blood donors from the beginning of the pandemic in NYC (considered March 1, 2020). These findings deviate with an earlier seroprevalence study in NYC showing 13.7% positivity. Collectively however, these data demonstrate that a low number of individuals have serologic evidence of infection during this "first wave" and suggest that the notion of "herd immunity" at rates of ~60% or higher are not near. Furthermore, the data presented herein show that the nature of the Ab-based immunity is not invariably associated with the development of NAb. While the blood donor population may not mimic precisely the NYC population as a whole, rapid assessment of seroprevalence in this cohort and serial reassessment could aid public health decision making.
Collapse
Affiliation(s)
- Daniel K. Jin
- Laboratory of Stem Cell Regenerative Research, Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY, United States of America
| | - Daniel J. Nesbitt
- Laboratory of Stem Cell Regenerative Research, Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY, United States of America
| | - Jenny Yang
- Laboratory of Stem Cell Regenerative Research, Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY, United States of America
| | - Haidee Chen
- Laboratory of Stem Cell Regenerative Research, Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY, United States of America
| | - Julie Horowitz
- Regeneron Genetics Center, Tarrytown, NY, United States of America
| | - Marcus Jones
- Regeneron Genetics Center, Tarrytown, NY, United States of America
| | | | - Timothy Carey
- Imanis Life Sciences, Rochester, MN, United States of America
| | - Samantha Reiter
- Imanis Life Sciences, Rochester, MN, United States of America
| | - Stephen J. Russell
- Vyriad, Inc., Rochester, MN, United States of America
- Imanis Life Sciences, Rochester, MN, United States of America
- Mayo Clinic Department of Molecular Medicine, Rochester, MN, United States of America
| | - Christos Kyratsous
- Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States of America
| | - Andrea Hooper
- Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States of America
| | - Jennifer Hamilton
- Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States of America
| | - Manuel Ferreira
- Regeneron Genetics Center, Tarrytown, NY, United States of America
| | - Sarah Deng
- Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States of America
| | - Donna Straus
- New York Blood Center Enterprises, New York, NY, United States of America
| | - Aris Baras
- Regeneron Genetics Center, Tarrytown, NY, United States of America
| | - Christopher D. Hillyer
- Laboratory of Stem Cell Regenerative Research, Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY, United States of America
- New York Blood Center Enterprises, New York, NY, United States of America
| | - Larry L. Luchsinger
- Laboratory of Stem Cell Regenerative Research, Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY, United States of America
| |
Collapse
|
8
|
Fidler TP, Xue C, Yalcinkaya M, Hardaway B, Abramowicz S, Xiao T, Liu W, Thomas DG, Hajebrahimi MA, Pircher J, Silvestre-Roig C, Kotini AG, Luchsinger LL, Wei Y, Westerterp M, Snoeck HW, Papapetrou EP, Schulz C, Massberg S, Soehnlein O, Ebert B, Levine RL, Reilly MP, Libby P, Wang N, Tall AR. The AIM2 inflammasome exacerbates atherosclerosis in clonal haematopoiesis. Nature 2021; 592:296-301. [PMID: 33731931 PMCID: PMC8038646 DOI: 10.1038/s41586-021-03341-5] [Citation(s) in RCA: 214] [Impact Index Per Article: 71.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2019] [Accepted: 02/08/2021] [Indexed: 02/07/2023]
Abstract
Clonal haematopoiesis, which is highly prevalent in older individuals, arises from somatic mutations that endow a proliferative advantage to haematopoietic cells. Clonal haematopoiesis increases the risk of myocardial infarction and stroke independently of traditional risk factors1. Among the common genetic variants that give rise to clonal haematopoiesis, the JAK2V617F (JAK2VF) mutation, which increases JAK-STAT signalling, occurs at a younger age and imparts the strongest risk of premature coronary heart disease1,2. Here we show increased proliferation of macrophages and prominent formation of necrotic cores in atherosclerotic lesions in mice that express Jak2VF selectively in macrophages, and in chimeric mice that model clonal haematopoiesis. Deletion of the essential inflammasome components caspase 1 and 11, or of the pyroptosis executioner gasdermin D, reversed these adverse changes. Jak2VF lesions showed increased expression of AIM2, oxidative DNA damage and DNA replication stress, and Aim2 deficiency reduced atherosclerosis. Single-cell RNA sequencing analysis of Jak2VF lesions revealed a landscape that was enriched for inflammatory myeloid cells, which were suppressed by deletion of Gsdmd. Inhibition of the inflammasome product interleukin-1β reduced macrophage proliferation and necrotic formation while increasing the thickness of fibrous caps, indicating that it stabilized plaques. Our findings suggest that increased proliferation and glycolytic metabolism in Jak2VF macrophages lead to DNA replication stress and activation of the AIM2 inflammasome, thereby aggravating atherosclerosis. Precise application of therapies that target interleukin-1β or specific inflammasomes according to clonal haematopoiesis status could substantially reduce cardiovascular risk.
Collapse
Affiliation(s)
- Trevor P. Fidler
- Division of Molecular Medicine, Department of Medicine, Columbia University Irving Medical Center, New York, NY, USA.,Correspondence and requests for materials should be addressed to T.P.F., N.W. or A.R.T. ; ;
| | - Chenyi Xue
- Cardiometabolic Precision Medicine Program, Cardiology Division, Department of Medicine, Columbia University Irving Medical Center, New York, NY, USA.,Irving Institute for Clinical and Translational Research, Columbia University Irving Medical Center, New York, NY, USA
| | - Mustafa Yalcinkaya
- Division of Molecular Medicine, Department of Medicine, Columbia University Irving Medical Center, New York, NY, USA
| | - Brian Hardaway
- Division of Molecular Medicine, Department of Medicine, Columbia University Irving Medical Center, New York, NY, USA
| | - Sandra Abramowicz
- Division of Molecular Medicine, Department of Medicine, Columbia University Irving Medical Center, New York, NY, USA
| | - Tong Xiao
- Division of Molecular Medicine, Department of Medicine, Columbia University Irving Medical Center, New York, NY, USA
| | - Wenli Liu
- Division of Molecular Medicine, Department of Medicine, Columbia University Irving Medical Center, New York, NY, USA
| | - David G. Thomas
- Division of Molecular Medicine, Department of Medicine, Columbia University Irving Medical Center, New York, NY, USA
| | - Mohammad Ali Hajebrahimi
- Medical Clinic I., Department of Cardiology, LMU Klinikum, Ludwig Maximilian University, Munich, Germany.,German Center for Cardiovascular Research (DZHK), Partner Site Munich Heart Alliance, Munich, Germany
| | - Joachim Pircher
- Medical Clinic I., Department of Cardiology, LMU Klinikum, Ludwig Maximilian University, Munich, Germany.,German Center for Cardiovascular Research (DZHK), Partner Site Munich Heart Alliance, Munich, Germany
| | - Carlos Silvestre-Roig
- German Center for Cardiovascular Research (DZHK), Partner Site Munich Heart Alliance, Munich, Germany.,Institute for Cardiovascular Prevention (IPEK), LMU Munich, Munich, Germany
| | - Andriana G. Kotini
- Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.,Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.,Black Family Stem Cell Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.,Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Larry L. Luchsinger
- Department of Medicine, Columbia Center for Human Development, Columbia University Irving Medical Center, New York, NY, USA
| | - Ying Wei
- Columbia University, New York, NY, USA
| | - Marit Westerterp
- Division of Molecular Medicine, Department of Medicine, Columbia University Irving Medical Center, New York, NY, USA.,Department of Pediatrics, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
| | - Hans-Willem Snoeck
- Department of Medicine, Columbia Center for Human Development, Columbia University Irving Medical Center, New York, NY, USA
| | - Eirini P. Papapetrou
- Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.,Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.,Black Family Stem Cell Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.,Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Christian Schulz
- Medical Clinic I., Department of Cardiology, LMU Klinikum, Ludwig Maximilian University, Munich, Germany.,German Center for Cardiovascular Research (DZHK), Partner Site Munich Heart Alliance, Munich, Germany
| | - Steffen Massberg
- Medical Clinic I., Department of Cardiology, LMU Klinikum, Ludwig Maximilian University, Munich, Germany.,German Center for Cardiovascular Research (DZHK), Partner Site Munich Heart Alliance, Munich, Germany
| | - Oliver Soehnlein
- German Center for Cardiovascular Research (DZHK), Partner Site Munich Heart Alliance, Munich, Germany.,Institute for Cardiovascular Prevention (IPEK), LMU Munich, Munich, Germany.,Department of Physiology and Pharmacology (FyFa), Karolinska Institute, Stockholm, Sweden
| | - Benjamin Ebert
- Department of Medical Oncology, Dana-Faber Cancer Institute, Boston, MA, USA.,Howard Hughes Medical Institute, Dana-Faber Cancer Institute, Boston, MA, USA
| | - Ross L. Levine
- Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.,Center for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - Muredach P. Reilly
- Cardiometabolic Precision Medicine Program, Cardiology Division, Department of Medicine, Columbia University Irving Medical Center, New York, NY, USA.,Irving Institute for Clinical and Translational Research, Columbia University Irving Medical Center, New York, NY, USA
| | - Peter Libby
- Department of Medicine, Cardiovascular Division, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA
| | - Nan Wang
- Division of Molecular Medicine, Department of Medicine, Columbia University Irving Medical Center, New York, NY, USA.,These authors jointly supervised this work: Nan Wang, Alan R. Tall.,Correspondence and requests for materials should be addressed to T.P.F., N.W. or A.R.T. ; ;
| | - Alan R. Tall
- Division of Molecular Medicine, Department of Medicine, Columbia University Irving Medical Center, New York, NY, USA.,These authors jointly supervised this work: Nan Wang, Alan R. Tall.,Correspondence and requests for materials should be addressed to T.P.F., N.W. or A.R.T. ; ;
| |
Collapse
|
9
|
Affiliation(s)
- Larry L Luchsinger
- Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY 10065, USA.
| | - Christopher D Hillyer
- Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY 10065, USA
| |
Collapse
|
10
|
Luchsinger LL, Ransegnola B, Jin D, Muecksch F, Weisblum Y, Bao W, George PJ, Rodriguez M, Tricoche N, Schmidt F, Gao C, Jawahar S, Pal M, Schnall E, Zhang H, Strauss D, Yazdanbakhsh K, Hillyer CD, Bieniasz PD, Hatziioannou T. Serological Assays Estimate Highly Variable SARS-CoV-2 Neutralizing Antibody Activity in Recovered COVID19 Patients. medRxiv 2020. [PMID: 32577675 PMCID: PMC7302251 DOI: 10.1101/2020.06.08.20124792] [Citation(s) in RCA: 22] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
The development of neutralizing antibodies (nAb) against SARS-CoV-2, following infection or vaccination, is likely to be critical for the development of sufficient population immunity to drive cessation of the COVID19 pandemic. A large number of serologic tests, platforms and methodologies are being employed to determine seroprevalence in populations to select convalescent plasmas for therapeutic trials, and to guide policies about reopening. However, tests have substantial variability in sensitivity and specificity, and their ability to quantitatively predict levels of nAb is unknown. We collected 370 unique donors enrolled in the New York Blood Center Convalescent Plasma Program between April and May of 2020. We measured levels of antibodies in convalescent plasma using commercially available SARS-CoV- 2 detection tests and in-house ELISA assays and correlated serological measurements with nAb activity measured using pseudotyped virus particles, which offer the most informative assessment of antiviral activity of patient sera against viral infection. Our data show that a large proportion of convalescent plasma samples have modest antibody levels and that commercially available tests have varying degrees of accuracy in predicting nAb activity. We found the Ortho Anti-SARS-CoV-2 Total Ig and IgG high throughput serological assays (HTSAs), as well as the Abbott SARS-CoV-2 IgG assay, quantify levels of antibodies that strongly correlate with nAb assays and are consistent with gold-standard ELISA assay results. These findings provide immediate clinical relevance to serology results that can be equated to nAb activity and could serve as a valuable ‘roadmap’ to guide the choice and interpretation of serological tests for SARS-CoV-2.
Collapse
Affiliation(s)
- Larry L Luchsinger
- Laboratory of Stem Cell Regenerative Research, Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY 10065, USA
| | - Brett Ransegnola
- Laboratory of Stem Cell Regenerative Research, Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY 10065, USA
| | - Daniel Jin
- Laboratory of Stem Cell Regenerative Research, Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY 10065, USA
| | - Frauke Muecksch
- Laboratory of Retrovirology, The Rockefeller University, New York, NY 10065, USA
| | - Yiska Weisblum
- Laboratory of Retrovirology, The Rockefeller University, New York, NY 10065, USA
| | - Weili Bao
- Laboratory of Complement Biology, Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY 10065, USA
| | - Parakkal Jovvian George
- Laboratory of Molecular Parasitology Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY 10065, USA
| | - Marilis Rodriguez
- Laboratory of Blood-Borne Parasites, Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY 10065, USA
| | - Nancy Tricoche
- Laboratory of Molecular Parasitology Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY 10065, USA
| | - Fabian Schmidt
- Laboratory of Retrovirology, The Rockefeller University, New York, NY 10065, USA
| | - Chengjie Gao
- Laboratory of Membrane Biology, Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY 10065, USA
| | - Shabnam Jawahar
- Laboratory of Molecular Parasitology Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY 10065, USA
| | - Mouli Pal
- Laboratory of Complement Biology, Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY 10065, USA
| | - Emily Schnall
- Laboratory of Molecular Parasitology Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY 10065, USA
| | - Huan Zhang
- Laboratory of Membrane Biology, Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY 10065, USA
| | - Donna Strauss
- New York Blood Center Enterprises, New York, NY 10065, USA
| | - Karina Yazdanbakhsh
- Laboratory of Complement Biology, Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY 10065, USA
| | - Christopher D Hillyer
- Laboratory of Stem Cell Regenerative Research, Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY 10065, USA.,New York Blood Center Enterprises, New York, NY 10065, USA
| | - Paul D Bieniasz
- Laboratory of Retrovirology, The Rockefeller University, New York, NY 10065, USA.,Howard Hughes Medical Institute, New York, NY 10016, USA
| | | |
Collapse
|
11
|
Ragnesola B, Jin D, Lamb CC, Shaz BH, Hillyer CD, Luchsinger LL. COVID19 antibody detection using lateral flow assay tests in a cohort of convalescent plasma donors. BMC Res Notes 2020; 13:372. [PMID: 32762746 PMCID: PMC7407441 DOI: 10.1186/s13104-020-05212-0] [Citation(s) in RCA: 32] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2020] [Accepted: 07/28/2020] [Indexed: 01/07/2023] Open
Abstract
Objective COVID19 has caused a global and ongoing pandemic. The need for population seroconversion data is apparent to monitor and respond to the pandemic. Using a lateral flow assay (LFA) testing platform, the seropositivity in 63 New York Blood Center (NYBC) Convelescent Plasma (CP) donor samples were evaluated for the presence of COVID19 specific IgG and IgM. Results CP donors showed diverse antibody result. Convalescent donor plasma contains SARS-CoV-2 specific antibodies. Weak antibody bands may identify low titer CP donors. LFA tests can identify antibody positive individuals that have recovered from COVID19. Confirming suspected cases using antibody detection could help inform the patient and the community as to the relative risk to future exposure and a better understanding of disease exposure.
Collapse
Affiliation(s)
- Brett Ragnesola
- New York Blood Center Lindsley F. Kimball Research Institute, 310 E 67th Street, New York, NY, 10065, USA
| | - Daniel Jin
- New York Blood Center Lindsley F. Kimball Research Institute, 310 E 67th Street, New York, NY, 10065, USA
| | - Christopher C Lamb
- BioSolutions Services, 92 Irving Avenue, Englewood Cliffs, NJ, 07632, USA. .,Department of Management and Entrepreneurship, Silberman College of Business, Fairleigh Dickinson University, Teaneck, NJ, USA. .,Weatherhead School of Management, Case Western Reserve University, Cleveland, OH, USA.
| | - Beth H Shaz
- New York Blood Center Lindsley F. Kimball Research Institute, 310 E 67th Street, New York, NY, 10065, USA
| | - Christopher D Hillyer
- New York Blood Center Lindsley F. Kimball Research Institute, 310 E 67th Street, New York, NY, 10065, USA
| | - Larry L Luchsinger
- New York Blood Center Lindsley F. Kimball Research Institute, 310 E 67th Street, New York, NY, 10065, USA.
| |
Collapse
|
12
|
Luchsinger LL, Strikoudis A, Danzl NM, Bush EC, Finlayson MO, Satwani P, Sykes M, Yazawa M, Snoeck HW. Harnessing Hematopoietic Stem Cell Low Intracellular Calcium Improves Their Maintenance In Vitro. Cell Stem Cell 2019; 25:225-240.e7. [PMID: 31178255 DOI: 10.1016/j.stem.2019.05.002] [Citation(s) in RCA: 56] [Impact Index Per Article: 11.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2018] [Revised: 03/20/2019] [Accepted: 04/26/2019] [Indexed: 12/17/2022]
Abstract
The specific cellular physiology of hematopoietic stem cells (HSCs) is underexplored, and their maintenance in vitro remains challenging. We discovered that culture of HSCs in low calcium increased their maintenance as determined by phenotype, function, and single-cell expression signature. HSCs are endowed with low intracellular calcium conveyed by elevated activity of glycolysis-fueled plasma membrane calcium efflux pumps and a low-bone-marrow interstitial fluid calcium concentration. Low-calcium conditions inhibited calpain proteases, which target ten-eleven translocated (TET) enzymes, of which TET2 was required for the effect of low calcium conditions on HSC maintenance in vitro. These observations reveal a physiological feature of HSCs that can be harnessed to improve their maintenance in vitro.
Collapse
Affiliation(s)
- Larry L Luchsinger
- Columbia Center of Human Development, Columbia University Irving Medical Center, New York, NY 10032, USA; Department of Medicine, Columbia University Irving Medical Center, New York, NY 10032, USA; New York Blood Center, Lindsley F. Kimball Research Institute, New York, NY 10065, USA
| | - Alexandros Strikoudis
- Columbia Center of Human Development, Columbia University Irving Medical Center, New York, NY 10032, USA; Department of Medicine, Columbia University Irving Medical Center, New York, NY 10032, USA
| | - Nichole M Danzl
- Department of Medicine, Columbia University Irving Medical Center, New York, NY 10032, USA; Columbia Center for Translational Immunology, Columbia University Irving Medical Center, New York, NY 10032, USA
| | - Erin C Bush
- JP Sulzberger Columbia Genome Center, Columbia University Irving Medical Center, New York, NY 10032, USA
| | - Michael O Finlayson
- JP Sulzberger Columbia Genome Center, Columbia University Irving Medical Center, New York, NY 10032, USA
| | - Prakash Satwani
- Columbia Center for Translational Immunology, Columbia University Irving Medical Center, New York, NY 10032, USA; Department of Pediatrics, Columbia University Irving Medical Center, New York, NY 10032, USA
| | - Megan Sykes
- Department of Medicine, Columbia University Irving Medical Center, New York, NY 10032, USA; Columbia Center for Translational Immunology, Columbia University Irving Medical Center, New York, NY 10032, USA; Department of Microbiology and Immunology, Columbia University Irving Medical Center, New York, NY 10032, USA
| | - Masayuki Yazawa
- Department of Rehabilitation and Regenerative Medicine, Columbia University Irving Medical Center, New York, NY 10032, USA
| | - Hans-Willem Snoeck
- Columbia Center of Human Development, Columbia University Irving Medical Center, New York, NY 10032, USA; Department of Medicine, Columbia University Irving Medical Center, New York, NY 10032, USA; Columbia Center for Translational Immunology, Columbia University Irving Medical Center, New York, NY 10032, USA; Department of Microbiology and Immunology, Columbia University Irving Medical Center, New York, NY 10032, USA.
| |
Collapse
|
13
|
Corrigan DJ, Luchsinger LL, Justino de Almeida M, Williams LJ, Strikoudis A, Snoeck HW. PRDM16 isoforms differentially regulate normal and leukemic hematopoiesis and inflammatory gene signature. J Clin Invest 2018; 128:3250-3264. [PMID: 29878897 DOI: 10.1172/jci99862] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/16/2018] [Accepted: 05/31/2018] [Indexed: 12/13/2022] Open
Abstract
PRDM16 is a transcriptional coregulator involved in translocations in acute myeloblastic leukemia (AML), myelodysplastic syndromes, and T acute lymphoblastic leukemia that is highly expressed in and required for the maintenance of hematopoietic stem cells (HSCs), and can be aberrantly expressed in AML. Prdm16 is expressed as full-length (fPrdm16) and short (sPrdm16) isoforms, the latter lacking the N-terminal PR domain. The role of both isoforms in normal and malignant hematopoiesis is unclear. We show here that fPrdm16 was critical for HSC maintenance, induced multiple genes involved in GTPase signaling, and repressed inflammation, while sPrdm16 supported B cell development biased toward marginal zone B cells and induced an inflammatory signature. In a mouse model of human MLL-AF9 leukemia, fPrdm16 extended latency, while sPrdm16 shortened latency and induced a strong inflammatory signature, including several cytokines and chemokines that are associated with myelodysplasia and with a worse prognosis in human AML. Finally, in human NPM1-mutant and in MLL-translocated AML, high expression of PRDM16, which negatively impacts outcome, was associated with inflammatory gene expression, thus corroborating the mouse data. Our observations demonstrate distinct roles for Prdm16 isoforms in normal HSCs and AML, and identify sPrdm16 as one of the drivers of prognostically adverse inflammation in leukemia.
Collapse
Affiliation(s)
- David J Corrigan
- Columbia Center of Human Development.,Department of Microbiology and Immunology
| | | | | | - Linda J Williams
- Columbia Center of Human Development.,Department of Medicine, and
| | | | - Hans-Willem Snoeck
- Columbia Center of Human Development.,Department of Microbiology and Immunology.,Department of Medicine, and.,Columbia Center for Translational Immunology, Columbia University Medical Center, New York, New York, USA
| |
Collapse
|
14
|
Chen X, Deng H, Churchill MJ, Luchsinger LL, Du X, Chu TH, Friedman RA, Middelhoff M, Ding H, Tailor YH, Wang ALE, Liu H, Niu Z, Wang H, Jiang Z, Renders S, Ho SH, Shah SV, Tishchenko P, Chang W, Swayne TC, Munteanu L, Califano A, Takahashi R, Nagar KK, Renz BW, Worthley DL, Westphalen CB, Hayakawa Y, Asfaha S, Borot F, Lin CS, Snoeck HW, Mukherjee S, Wang TC. Bone Marrow Myeloid Cells Regulate Myeloid-Biased Hematopoietic Stem Cells via a Histamine-Dependent Feedback Loop. Cell Stem Cell 2017; 21:747-760.e7. [PMID: 29198940 PMCID: PMC5975960 DOI: 10.1016/j.stem.2017.11.003] [Citation(s) in RCA: 55] [Impact Index Per Article: 7.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/18/2017] [Revised: 08/04/2017] [Accepted: 11/01/2017] [Indexed: 01/21/2023]
Abstract
Myeloid-biased hematopoietic stem cells (MB-HSCs) play critical roles in recovery from injury, but little is known about how they are regulated within the bone marrow niche. Here we describe an auto-/paracrine physiologic circuit that controls quiescence of MB-HSCs and hematopoietic progenitors marked by histidine decarboxylase (Hdc). Committed Hdc+ myeloid cells lie in close anatomical proximity to MB-HSCs and produce histamine, which activates the H2 receptor on MB-HSCs to promote their quiescence and self-renewal. Depleting histamine-producing cells enforces cell cycle entry, induces loss of serial transplant capacity, and sensitizes animals to chemotherapeutic injury. Increasing demand for myeloid cells via lipopolysaccharide (LPS) treatment specifically recruits MB-HSCs and progenitors into the cell cycle; cycling MB-HSCs fail to revert into quiescence in the absence of histamine feedback, leading to their depletion, while an H2 agonist protects MB-HSCs from depletion after sepsis. Thus, histamine couples lineage-specific physiological demands to intrinsically primed MB-HSCs to enforce homeostasis.
Collapse
Affiliation(s)
- Xiaowei Chen
- Division of Digestive and Liver Disease, Department of Medicine, Columbia University Medical Center, New York, 10032, USA,Division of Hematology/Oncology, Department of Medicine, Columbia University Medical Center, New York, 10032, USA,Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, 10032, USA
| | - Huan Deng
- Division of Digestive and Liver Disease, Department of Medicine, Columbia University Medical Center, New York, 10032, USA,Division of Hematology/Oncology, Department of Medicine, Columbia University Medical Center, New York, 10032, USA,Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, 10032, USA,Department of Pathology, and Molecular Medicine and Genetics Center, The Fourth Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, 330003, China
| | - Michael J. Churchill
- Division of Hematology/Oncology, Department of Medicine, Columbia University Medical Center, New York, 10032, USA
| | - Larry L. Luchsinger
- Columbia Center for Translational Immunology, Columbia University Medical Center, New York, 10032, USA,Center for Human Development, Columbia University Medical Center, New York, New York 10032, USA
| | - Xing Du
- Division of Hematology/Oncology, Department of Medicine, Columbia University Medical Center, New York, 10032, USA
| | - Timothy H. Chu
- Division of Digestive and Liver Disease, Department of Medicine, Columbia University Medical Center, New York, 10032, USA,Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, 10032, USA
| | - Richard A. Friedman
- Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, 10032, USA,Biomedical Informatics Shared Resource, Herbert Irving Comprehensive Cancer Center, and Department of Biomedical Informatics, Columbia University Medical Center, New York, 10032, USA
| | - Moritz Middelhoff
- Division of Digestive and Liver Disease, Department of Medicine, Columbia University Medical Center, New York, 10032, USA,Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, 10032, USA
| | - Hongxu Ding
- Biomedical Informatics Shared Resource, Herbert Irving Comprehensive Cancer Center, and Department of Biomedical Informatics, Columbia University Medical Center, New York, 10032, USA,Department of Systems Biology, Columbia University, New York, 10032, USA
| | - Yagnesh H. Tailor
- Division of Digestive and Liver Disease, Department of Medicine, Columbia University Medical Center, New York, 10032, USA,Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, 10032, USA
| | - Alexander L. E. Wang
- Division of Digestive and Liver Disease, Department of Medicine, Columbia University Medical Center, New York, 10032, USA,Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, 10032, USA
| | - Haibo Liu
- Division of Digestive and Liver Disease, Department of Medicine, Columbia University Medical Center, New York, 10032, USA,Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, 10032, USA
| | - Zhengchuan Niu
- Division of Digestive and Liver Disease, Department of Medicine, Columbia University Medical Center, New York, 10032, USA,Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, 10032, USA,Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, 200032, China
| | - Hongshan Wang
- Division of Digestive and Liver Disease, Department of Medicine, Columbia University Medical Center, New York, 10032, USA,Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, 10032, USA,Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, 200032, China
| | - Zhenyu Jiang
- Division of Digestive and Liver Disease, Department of Medicine, Columbia University Medical Center, New York, 10032, USA,Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, 10032, USA
| | - Simon Renders
- Division of Hematology/Oncology, Department of Medicine, Columbia University Medical Center, New York, 10032, USA,Division of Stem Cells and Cancer, German Cancer Research Center (DKFZ), DKFZ-ZMBH Alliance and Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM gGmbH) 69120 Heidelberg, Germany
| | - Siu-Hong Ho
- Columbia Center for Translational Immunology, Columbia University Medical Center, New York, 10032, USA
| | - Spandan V. Shah
- Columbia Center for Translational Immunology, Columbia University Medical Center, New York, 10032, USA
| | - Pavel Tishchenko
- Columbia Center for Translational Immunology, Columbia University Medical Center, New York, 10032, USA
| | - Wenju Chang
- Division of Digestive and Liver Disease, Department of Medicine, Columbia University Medical Center, New York, 10032, USA,Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, 10032, USA,Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, 200032, China
| | - Theresa C. Swayne
- Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, 10032, USA
| | - Laura Munteanu
- Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, 10032, USA
| | - Andrea Califano
- Biomedical Informatics Shared Resource, Herbert Irving Comprehensive Cancer Center, and Department of Biomedical Informatics, Columbia University Medical Center, New York, 10032, USA,Department of Systems Biology, Columbia University, New York, 10032, USA
| | - Ryota Takahashi
- Division of Digestive and Liver Disease, Department of Medicine, Columbia University Medical Center, New York, 10032, USA,Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, 10032, USA
| | - Karan K. Nagar
- Division of Digestive and Liver Disease, Department of Medicine, Columbia University Medical Center, New York, 10032, USA,Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, 10032, USA
| | - Bernhard W. Renz
- Division of Digestive and Liver Disease, Department of Medicine, Columbia University Medical Center, New York, 10032, USA,Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, 10032, USA,Department of General, Visceral and Transplantation Surgery, Hospital of the University of Munich, D-81377, Munich, Germany
| | - Daniel L. Worthley
- Division of Digestive and Liver Disease, Department of Medicine, Columbia University Medical Center, New York, 10032, USA,Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, 10032, USA,School of Medicine, University of Adelaide, SA 5005, Australia,Cancer Theme, SAHMRI, Adelaide, SA 5005, Australia
| | - C. Benedikt Westphalen
- Division of Digestive and Liver Disease, Department of Medicine, Columbia University Medical Center, New York, 10032, USA,Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, 10032, USA,Department of Medicine III, University Hospital, LMU Munich, D-81377, Munich, Germany
| | - Yoku Hayakawa
- Division of Digestive and Liver Disease, Department of Medicine, Columbia University Medical Center, New York, 10032, USA,Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, 10032, USA,Department of Gastroenterology, Graduate School of Medicine, the University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, Tokyo 113-8655, Japan
| | - Samuel Asfaha
- Division of Digestive and Liver Disease, Department of Medicine, Columbia University Medical Center, New York, 10032, USA,Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, 10032, USA,Department of Medicine, University of Western Ontario, London, ON N6A 5W9, Canada
| | - Florence Borot
- Division of Hematology/Oncology, Department of Medicine, Columbia University Medical Center, New York, 10032, USA
| | - Chyuan-Sheng Lin
- Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, 10032, USA,Department of Pathology and Cell Biology, Columbia University Medical Center, New York, 10032, USA
| | - Hans-Willem Snoeck
- Columbia Center for Translational Immunology, Columbia University Medical Center, New York, 10032, USA,Center for Human Development, Columbia University Medical Center, New York, New York 10032, USA,Department of Medicine, Columbia University Medical Center, New York, New York 10032, USA,Department of Microbiology and Immunology, Columbia University Medical Center, New York, New York 10032, USA
| | - Siddhartha Mukherjee
- Division of Hematology/Oncology, Department of Medicine, Columbia University Medical Center, New York, 10032, USA,Correspondence: (S.M.), (T.C.W.)
| | - Timothy C. Wang
- Division of Digestive and Liver Disease, Department of Medicine, Columbia University Medical Center, New York, 10032, USA,Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, 10032, USA,Correspondence: (S.M.), (T.C.W.)
| |
Collapse
|
15
|
de Almeida MJ, Luchsinger LL, Corrigan DJ, Williams LJ, Snoeck HW. Dye-Independent Methods Reveal Elevated Mitochondrial Mass in Hematopoietic Stem Cells. Cell Stem Cell 2017; 21:725-729.e4. [PMID: 29198942 DOI: 10.1016/j.stem.2017.11.002] [Citation(s) in RCA: 134] [Impact Index Per Article: 19.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2017] [Revised: 09/25/2017] [Accepted: 11/01/2017] [Indexed: 02/03/2023]
Abstract
Hematopoietic stem cells (HSCs) produce most cellular energy through glycolysis rather than through mitochondrial respiration. Consistent with this notion, mitochondrial mass has been reported to be low in HSCs. However, we found that staining with MitoTracker Green, a commonly used dye to measure mitochondrial content, leads to artefactually low fluorescence specifically in HSCs because of dye efflux. Using mtDNA quantification, enumeration of mitochondrial nucleoids, and fluorescence intensity of a genetically encoded mitochondrial reporter, we unequivocally show here that HSCs and multipotential progenitors (MPPs) have higher mitochondrial mass than lineage-committed progenitors and mature cells. Despite similar mitochondrial mass, respiratory capacity of MPPs exceeds that of HSCs. Furthermore, although elevated mitophagy has been invoked to explain low mitochondrial mass in HSCs, we observed that mitochondrial turnover capacity is comparatively low in HSCs. We propose that the role of mitochondria in HSC biology may have to be revisited in light of these findings.
Collapse
Affiliation(s)
- Mariana Justino de Almeida
- Columbia Center for Human Development, Columbia University Medical Center, New York, NY 10032, USA; Department of Microbiology and Immunology, Columbia University Medical Center, New York, NY 10032, USA
| | - Larry L Luchsinger
- Columbia Center for Human Development, Columbia University Medical Center, New York, NY 10032, USA; Department of Medicine, Columbia University Medical Center, New York, NY 10032, USA
| | - David J Corrigan
- Columbia Center for Human Development, Columbia University Medical Center, New York, NY 10032, USA; Department of Microbiology and Immunology, Columbia University Medical Center, New York, NY 10032, USA
| | - Linda J Williams
- Columbia Center for Human Development, Columbia University Medical Center, New York, NY 10032, USA
| | - Hans-Willem Snoeck
- Columbia Center for Human Development, Columbia University Medical Center, New York, NY 10032, USA; Department of Microbiology and Immunology, Columbia University Medical Center, New York, NY 10032, USA; Department of Medicine, Columbia University Medical Center, New York, NY 10032, USA.
| |
Collapse
|
16
|
Adams WC, Chen YH, Kratchmarov R, Yen B, Nish SA, Lin WHW, Rothman NJ, Luchsinger LL, Klein U, Busslinger M, Rathmell JC, Snoeck HW, Reiner SL. Anabolism-Associated Mitochondrial Stasis Driving Lymphocyte Differentiation over Self-Renewal. Cell Rep 2017; 17:3142-3152. [PMID: 28009285 DOI: 10.1016/j.celrep.2016.11.065] [Citation(s) in RCA: 76] [Impact Index Per Article: 10.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/26/2016] [Revised: 10/24/2016] [Accepted: 11/21/2016] [Indexed: 01/15/2023] Open
Abstract
Regeneration requires related cells to diverge in fate. We show that activated lymphocytes yield sibling cells with unequal elimination of aged mitochondria. Disparate mitochondrial clearance impacts cell fate and reflects larger constellations of opposing metabolic states. Differentiation driven by an anabolic constellation of PI3K/mTOR activation, aerobic glycolysis, inhibited autophagy, mitochondrial stasis, and ROS production is balanced with self-renewal maintained by a catabolic constellation of AMPK activation, mitochondrial elimination, oxidative metabolism, and maintenance of FoxO1 activity. Perturbations up and down the metabolic pathways shift the balance of nutritive constellations and cell fate owing to self-reinforcement and reciprocal inhibition between anabolism and catabolism. Cell fate and metabolic state are linked by transcriptional regulators, such as IRF4 and FoxO1, with dual roles in lineage and metabolic choice. Instructing some cells to utilize nutrients for anabolism and differentiation while other cells catabolically self-digest and self-renew may enable growth and repair in metazoa.
Collapse
Affiliation(s)
- William C Adams
- Department of Microbiology and Immunology and Department of Pediatrics, Columbia University Medical Center, New York, NY 10032, USA
| | - Yen-Hua Chen
- Department of Microbiology and Immunology and Department of Pediatrics, Columbia University Medical Center, New York, NY 10032, USA
| | - Radomir Kratchmarov
- Department of Microbiology and Immunology and Department of Pediatrics, Columbia University Medical Center, New York, NY 10032, USA
| | - Bonnie Yen
- Department of Microbiology and Immunology and Department of Pediatrics, Columbia University Medical Center, New York, NY 10032, USA
| | - Simone A Nish
- Department of Microbiology and Immunology and Department of Pediatrics, Columbia University Medical Center, New York, NY 10032, USA
| | - Wen-Hsuan W Lin
- Department of Microbiology and Immunology and Department of Pediatrics, Columbia University Medical Center, New York, NY 10032, USA
| | - Nyanza J Rothman
- Department of Microbiology and Immunology and Department of Pediatrics, Columbia University Medical Center, New York, NY 10032, USA
| | - Larry L Luchsinger
- Department of Medicine and Department of Microbiology and Immunology, Columbia University Medical Center, New York, NY 10032, USA
| | - Ulf Klein
- Department of Pathology and Department of Microbiology and Immunology, Columbia University Medical Center, New York, NY 10032, USA
| | - Meinrad Busslinger
- Research Institute of Molecular Pathology, Vienna Biocenter, 1030 Vienna, Austria
| | - Jeffrey C Rathmell
- Vanderbilt Centre for Immunobiology, Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN 37232, USA
| | - Hans-Willem Snoeck
- Department of Medicine and Department of Microbiology and Immunology, Columbia University Medical Center, New York, NY 10032, USA
| | - Steven L Reiner
- Department of Microbiology and Immunology and Department of Pediatrics, Columbia University Medical Center, New York, NY 10032, USA.
| |
Collapse
|
17
|
Luchsinger LL, de Almeida MJ, Corrigan DJ, Mumau M, Snoeck HW. Mitofusin 2 maintains haematopoietic stem cells with extensive lymphoid potential. Nature 2016; 529:528-31. [PMID: 26789249 PMCID: PMC5106870 DOI: 10.1038/nature16500] [Citation(s) in RCA: 174] [Impact Index Per Article: 21.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2015] [Accepted: 11/30/2015] [Indexed: 12/18/2022]
Abstract
Haematopoietic stem cells (HSCs), which sustain production of all blood cell lineages, rely on glycolysis for ATP production, yet little attention has been paid to the role of mitochondria. Here we show in mice that the short isoform of a critical regulator of HSCs, Prdm16 (refs 4, 5), induces mitofusin 2 (Mfn2), a protein involved in mitochondrial fusion and in tethering of mitochondria to the endoplasmic reticulum. Overexpression and deletion studies, including single-cell transplantation assays, revealed that Mfn2 is specifically required for the maintenance of HSCs with extensive lymphoid potential, but not, or less so, for the maintenance of myeloid-dominant HSCs. Mfn2 increased buffering of intracellular Ca(2+), an effect mediated through its endoplasmic reticulum-mitochondria tethering activity, thereby negatively regulating nuclear translocation and transcriptional activity of nuclear factor of activated T cells (Nfat). Nfat inhibition rescued the effects of Mfn2 deletion in HSCs, demonstrating that negative regulation of Nfat is the prime downstream mechanism of Mfn2 in the maintenance of HSCs with extensive lymphoid potential. Mitochondria therefore have an important role in HSCs. These findings provide a mechanism underlying clonal heterogeneity among HSCs and may lead to the design of approaches to bias HSC differentiation into desired lineages after transplantation.
Collapse
Affiliation(s)
- Larry L Luchsinger
- Columbia Center for Translational Immunology, Columbia University Medical Center, New York, New York 10032, USA.,Department of Medicine, Columbia University Medical Center, New York, New York 10032, USA
| | - Mariana Justino de Almeida
- Columbia Center for Translational Immunology, Columbia University Medical Center, New York, New York 10032, USA.,Department of Microbiology and Immunology, Columbia University Medical Center, New York, New York 10032, USA
| | - David J Corrigan
- Columbia Center for Translational Immunology, Columbia University Medical Center, New York, New York 10032, USA.,Department of Microbiology and Immunology, Columbia University Medical Center, New York, New York 10032, USA
| | - Melanie Mumau
- Columbia Center for Translational Immunology, Columbia University Medical Center, New York, New York 10032, USA.,Department of Microbiology and Immunology, Columbia University Medical Center, New York, New York 10032, USA
| | - Hans-Willem Snoeck
- Columbia Center for Translational Immunology, Columbia University Medical Center, New York, New York 10032, USA.,Department of Medicine, Columbia University Medical Center, New York, New York 10032, USA.,Department of Microbiology and Immunology, Columbia University Medical Center, New York, New York 10032, USA
| |
Collapse
|
18
|
Luchsinger LL, Patenaude CA, Smith BD, Layne MD. Myocardin-related transcription factor-A complexes activate type I collagen expression in lung fibroblasts. J Biol Chem 2011; 286:44116-44125. [PMID: 22049076 DOI: 10.1074/jbc.m111.276931] [Citation(s) in RCA: 99] [Impact Index Per Article: 7.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023] Open
Abstract
Pulmonary fibrosis is characterized by the excessive deposition of a collagen-rich extracellular matrix. The accumulation of collagen within the lung interstitium leads to impaired respiratory function. Furthermore, smooth muscle actin-positive myofibroblasts within the fibrotic lung contribute to disease progression. Because collagen and smooth muscle cell α-actin are coordinately expressed in the setting of fibrosis, the hypothesis was tested that specific transcriptional regulators of the myocardin family might also regulate collagen gene expression in myofibroblasts. Myocardin-related transcription factors (MRTFs), through their interaction with the serum-response factor (SRF) on CArG box regulatory elements (CC(A/T)6GG), are important regulators of myofibroblast differentiation. MRTF-A transactivated type I collagen gene reporters as much as 100-fold in lung myofibroblasts. Loss of functional MRTF-A using either a dominant negative MRTF-A isoform, shRNA targeting MRTF-A, or genetic deletion of MRTF-A in lung fibroblasts significantly disrupted type I collagen synthesis relative to controls. Analysis of the COL1A2 proximal promoter revealed a noncanonical CArG box (CCAAACTTGG), flanked by several Sp1 sites important for MRTF-A activation. Chromatin immunoprecipitation experiments confirmed the co-localization of MRTF-A, SRF, and Sp1 bound to the same region of the COL1A2 promoter. Mutagenesis of either the noncanonical CArG box or the Sp1 sites significantly disrupted MRTF-A activation of COL1A2. Together, our findings show that MRTF-A is an important regulator of collagen synthesis in lung fibroblasts and exhibits a dependence on both SRF and Sp1 function to enhance collagen expression.
Collapse
Affiliation(s)
- Larry L Luchsinger
- Department of Biochemistry, Boston University School of Medicine, Boston, Massachusetts 02118
| | - Cassandra A Patenaude
- Department of Biochemistry, Boston University School of Medicine, Boston, Massachusetts 02118
| | - Barbara D Smith
- Department of Biochemistry, Boston University School of Medicine, Boston, Massachusetts 02118.
| | - Matthew D Layne
- Department of Biochemistry, Boston University School of Medicine, Boston, Massachusetts 02118.
| |
Collapse
|